Your AI-Trained Oncology Knowledge Connection!

Giants vs. Jets Face-Off: Treatment Options and the Present Status of Non-Small Cell Lung Tumors in Patients who Test Positive for ALK : Episode 6

Optimal Approach for PD-L1 >50%

December 21, 2023

By Deborah Doroshow, MD
Neel Chudgar, MD

Opinion

Video

Discussion regarding immunotherapy alone or in combination with chemotherapy for patients with NSCLC that are PD-L1 >50%.

EP: 1.Introduction of the Debate Between Jets v. Giants

EP: 2.Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial

EP: 3.Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer

EP: 4.Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?

EP: 5.Treatment for Borderline Resectable Patients With NSCLC

EP: 6.Optimal Approach for PD-L1 >50%

EP: 7.Cancer Network Faceoff: Conclusion of the Event and Presentation of Awards

EP: 8.Clinicians Face Off Regarding New Trials in NSCLC Space

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.

In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.

Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences

All rights reserved.